Sin Nombre Virus

Sin Nambre virus (SNV), meaning "unnamed virus" in Spanish, is an important zoonotic pathogen and the main pathogen of Hantavirus pulmonary syndrome (HPS), also known as Hantavirus cardiorespiratory syndrome in North America. Its discovery marks a critical moment in the understanding of emerging infectious diseases. The virus was quickly identified as a previously unknown Hantavirus, with its main host identified as Peromyscus maniculatus, a common and widely distributed North American rodent. Unlike human diseases, SNV infection in deer mice can lead to persistent asymptomatic infections, allowing the virus to persist in rodent populations and be excreted in their excrement. It is estimated that SNV has been spreading in rodent populations for at least 32000 years, indicating a long-term evolutionary relationship with its host. SNV is the main culprit of most HPS cases in North America, with a high mortality rate of over 35-50% in history.

Figure 1. Structure and genome of Sin Nombre virus (SNV). (Jacob, Andrew T., et al.2023)

Host Targets

1. β3 Integrin

As the primary cellular receptor for SNV, β3 integrin is a key host target for preventing viral entry. Inhibitors that block the interaction between SNV Gn/Gc and β3 integrin could prevent infection of host cells.

• Integrin Antagonists: Peptides and small molecules that bind to β3 integrin have been shown to inhibit SNV entry in vitro. These antagonists prevent the virus from attaching to host cells, reducing viral load and tissue damage.
• Antibody-Mediated Blockade: Monoclonal antibodies targeting β3 integrin can block SNV binding and entry, providing a potential therapeutic strategy for preventing infection.

2. Pro-Inflammatory Pathways

The excessive inflammatory response during SNV infection contributes to the pathogenesis of HCPS. Targeting pro-inflammatory cytokines and chemokines could reduce vascular permeability and tissue damage.

• Cytokine Inhibitors: Drugs that block the activity of TNF-α, IL-6, or other pro-inflammatory cytokines have been proposed as adjunctive therapies for HCPS. These inhibitors could reduce the severity of pulmonary edema and cardiogenic shock by dampening the inflammatory response.
• Chemokine Receptor Antagonists: Inhibitors of chemokine receptors (e.g., CXCR3, CCR2) could prevent the recruitment of immune cells to the lungs, reducing tissue inflammation and damage.

3. Host Signaling Pathways Activated by SNV Glycoproteins

Binding of Gn/Gc to host receptors triggers intracellular signaling cascades that support viral replication and promote endothelial dysfunction. Targeting these pathways mitigates both viral entry and pathogenesis linked to glycoprotein-host interactions.

Virus Structure and Genome Organization

• Virus Morphology

The SNV virus particles are enveloped and polymorphic, typically appearing as spherical particles with a diameter of approximately 80-120nm. The viral envelope originates from the host cell membrane and is embedded with viral glycoproteins that form surface protrusions. These glycoproteins are crucial for receptor binding and entry into host cells. Underneath the envelope is the core of the viral particle, which contains the viral genome complexed with nucleocapsid protein and RNA dependent RNA polymerase

• Genomic Structure

The SNV genome consists of a single stranded RNA with negative sense, divided into three segments named Large (L), Medium (M), and Small (S). This triple genome is a hallmark of the Bunyaviridae family.

L fragment: encodes the L protein, which functions as an RNA dependent RNA polymerase responsible for virus replication and transcription.

M fragment: encodes glycoprotein precursor (GPC), which is co translated and cleaved by cellular proteases into two mature envelope glycoproteins Gn (G1) and Gc (G2). These proteins mediate the attachment and fusion of viruses with host cell membranes, and are the main targets for neutralizing antibodies.

S fragment: encodes the nucleocapsid (N) protein. This protein tightly binds to the viral RNA genome, forming ribonucleoprotein complexes (RNPs) that protect RNA and serve as a functional template for polymerase.

Diagnostic Method

Rapid and accurate diagnosis of SNV infection is crucial for patient management and public health response. Diagnosis is based on a combination of clinical suspicion and laboratory testing.

• Serological testing: The most common and critical diagnostic method is to use enzyme-linked immunosorbent assay (ELISA) to detect SNV specific IgM and IgG antibodies. Due to its high immunogenicity, nucleocapsid (N) proteins are common targets for these tests.
• Molecular technology: Reverse transcription polymerase chain reaction (RT-PCR) can detect viral RNA in clinical specimens, such as blood or tissue, especially in the early stages of viremia.
• Immunohistochemistry (IHC): This technique typically uses specific antibodies to detect viral antigens in formalin fixed tissues after death and is a valuable tool for confirming infection

Anti-SNV Antibody

Eastern Equine Encephalitis Virus Antigens